A Phase 2 interventional study of MAS825 and MAS825 Placebo in Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP), sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Coronary Disease with a site in Germany — 9 open to participants now, 13 under way, 1 of them phase 3. Coronary Disease · Germany.
Among the 123 studies in Coronary Disease with a site in Germany, this one is the 72nd largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, and was the 116th registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →9 of the 123 studies in Coronary Disease with a site in Germany are open now. Recruiting first, the newest first:
Philipps University Marburg · Sites in Germany
Ages 30+
Technical University of Munich · Sites in Germany
Ages 50+
Weill Medical College of Cornell University · Sites in Germany, United States, Austria and 3 more countries
Ages 18+
iATROS GmbH · Sites in Germany
Ages 18+
Robocath · Sites in Germany, Belgium, France and 3 more countries
Ages 18–120
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 16 · Phase 4 30
First in 1998; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 322 across the 84 interventional studies, 578 across the 39 observational. Of the 93 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 123 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Coronary Disease with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT04433052Tampere UniversityClinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD | 2026-12 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
| NCT06796582Technical University of MunichReliability of Multiple-Repetition-Maximum Tests in Patients With Cardiovascular Disease or Risk Factors | 2027-02 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
Add all 5 to your calendar (.ics) → With an account.
Among the 123 studies in Coronary Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency [VAF] ≥2%).
This was a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study.
The study consisted of a screening period up to 30 days; a treatment period of approximately 12 weeks with an end of treatment (EOT) visit on Day 85, which is one day after the last dose of DFV890 or placebo; a follow-up period of approximately 1 week; and a standard safety follow-up call approximately 30 days following the last dose. The overall study duration is approximately 21 weeks.
Participants were randomized to one of five treatment sequences. Based on the treatment sequence assignments, participants started on either a combination of MAS825 and placebo, DFV890 and placebo, or placebo and placebo on Day 1, and then, within each DFV890 treatment sequence, participants received up-titrating doses of DFV890 or placebo at the corresponding study visits. None of the treatment sequences included a combination of both active DFV890 and active MAS825.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
Drug: MAS825 · Drug: DFV890 placebo
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.
Drug: MAS825 Placebo · Drug: DFV890 · Drug: DFV890 placebo
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.
Drug: MAS825 Placebo · Drug: DFV890 · Drug: DFV890 placebo
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.
Drug: MAS825 Placebo · Drug: DFV890
On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.
Drug: MAS825 Placebo · Drug: DFV890 placebo
Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.
Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model
Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.
Time frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.
Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state
Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.
Time frame: After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignment
MAS825 Serum Concentrations
MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.
Time frame: Day 22, Day 43, Day 64 and Day 85
Participants were randomized in a 4:4:4:1:1 ratio to one of the five treatment sequences.
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 |
|---|---|---|---|---|---|
| Started | 11 | 8 | 8 | 2 | 2 |
| Pd analysis set | 11 | 8 | 8 | 2 | 2 |
| Safety analysis set | 11 | 8 | 8 | 2 | 2 |
| Pk analysis set | 11 | 7 | 7 | 2 | 0 |
| Completed | 11 | 7 | 5 | 2 | 1 |
| Not completed | 0 | 1 | 3 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Subject decision | 0 | 0 | 1 | 0 | 1 |
Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.
| ratio serum levels of IL-6 | DFV890 10 mg | DFV890 25 mg | DFV890 50 mg | DFV890 100 mg | Placebo |
|---|---|---|---|---|---|
| Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model | 0.8602 (0.7117 to 1.0397) | 0.7558 (0.6615 to 0.8637) | 0.7002 (0.6146 to 0.7976) | 0.6657 (0.5495 to 0.8064) | 1.1219 (0.9594 to 1.3120) |
Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.
| ratio serum levels of IL-18 | DFV890 10 mg | DFV890 25 mg | DFV890 50 mg | DFV890 100 mg | Placebo |
|---|---|---|---|---|---|
| Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model | 0.9088 (0.8825 to 0.9358) | 0.9087 (0.8825 to 0.9357) | 0.9087 (0.8825 to 0.9357) | 0.9087 (0.8825 to 0.9357) | 0.9767 (0.9427 to 1.0119) |
Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.
| ratio serum levels if IL-6 | MAS825 | Placebo |
|---|---|---|
| Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model | 0.5406 (0.4287 to 0.6818) | 1.1335 (0.9488 to 1.3541) |
Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.
| ng/mL | DFV890 10 mg | DFV890 25 mg | DFV890 50 mg | DFV890 100 mg |
|---|---|---|---|---|
| Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state | 144 ± 72.7 | 427 ± 363 | 1200 ± 914 | 2730 ± 3930 |
MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.
| ng/mL | Treatment Sequence 1 |
|---|---|
| Day 22 | 35750.0 ± 8360.62 |
| Day 43 | 22285.7 ± 9080.64 |
| Day 64 | 10574.0 ± 4346.20 |
| EOT (Day 85) | 7790.0 ± 4403.56 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DFV890 10 mg | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| DFV890 25 mg | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| DFV890 50 mg | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| DFV890 100 mg | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| MAS825 | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Placebo Sessions | 0/22 (0%) | 0/22 (0%) | 9/22 (40.9%) |
| Placebo Participants | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| DFV890 100 mg Follow-up | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| MAS825 Follow-up | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Placebo Follow-up | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | DFV890 10 mg | DFV890 25 mg | DFV890 50 mg | DFV890 100 mg | MAS825 | Placebo Sessions | Placebo Participants | DFV890 100 mg Follow-up | MAS825 Follow-up | Placebo Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/10 | 0/16 | 0/9 | 0/16 | 2/11 | 2/22 | 2/18 | 0/16 | 0/11 | 0/2 |
| HeadacheNervous system disorders | 0/10 | 0/16 | 0/9 | 0/16 | 2/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| Bacterial infectionInfections and infestations | 0/10 | 0/16 | 1/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/10 | 1/16 | 0/9 | 0/16 | 0/11 | 2/22 | 2/18 | 0/16 | 0/11 | 0/2 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/10 | 0/16 | 1/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/10 | 0/16 | 1/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| Amylase increasedInvestigations | 1/10 | 0/16 | 0/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| Lipase increasedInvestigations | 1/10 | 0/16 | 0/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 0/11 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 1/16 | 0/9 | 0/16 | 1/11 | 1/22 | 1/18 | 0/16 | 0/11 | 0/2 |
| EnteritisGastrointestinal disorders | 0/10 | 0/16 | 0/9 | 0/16 | 0/11 | 0/22 | 0/18 | 0/16 | 1/11 | 0/2 |
| Age, Categorical(Participants) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 3 | 0 | 1 | 8 |
| >=65 years | 8 | 7 | 5 | 2 | 1 | 23 |
| Age, Continuous(years) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 68.9 ± 6.44 | 70.3 ± 5.92 | 70.3 ± 7.27 | 76.0 ± 5.66 | 65.5 ± 6.36 | 69.8 ± 6.40 |
| Sex: Female, Male(Participants) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 2 | 3 | 1 | 0 | 7 |
| Male | 10 | 6 | 5 | 1 | 2 | 24 |
| Race/Ethnicity, Customized(Participants) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Total |
|---|---|---|---|---|---|---|
| Black or African American | 0 | 1 | 1 | 0 | 0 | 2 |
| White | 11 | 7 | 7 | 2 | 2 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2024 to primary completion in Oct 2024, 8 months.
Results were first posted in Mar 2026, 1 year 5 months after primary completion.
Of 19 phase 2 interventional studies under Coronary Disease, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arumakimig · NLRP3 Inhibitor DFV890